Journal Articles

  1. & Molecular pathology of Multiple Sclerosis lesions reveals a heterogeneous expression pattern of genes involved in oligodendrogliogenesis. Experimental Neurology
  2. & Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. Annals of Neurology
  3. & Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59. Multiple Sclerosis Journal
  4. & Tissue microarray methodology identifies complement pathway activation and dysregulation in progressive multiple sclerosis. Brain Pathology
  5. & Complement is activated in progressive multiple sclerosis cortical grey matter lesions. Journal of Neuroinflammation 13(1)
  6. & Extensive grey matter pathology in the cerebellum in multiple sclerosis is linked to inflammation in the subarachnoid space. Neuropathology and Applied Neurobiology 41(6), 798-813.
  7. & Complement activation in multiple sclerosis plaques: an immunohistochemical analysis. Acta Neuropathologica Communications 2(1), 53
  8. & Cortical grey matter demyelination can be induced by elevated pro-inflammatory cytokines in the subarachnoid space of MOG-immunized rats. Brain
  9. & Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain 135(10), 2925-2937.
  10. & Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 134(9), 2755-2771.
  11. & Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Annals of Neurology 69(3), 481-492.
  12. & Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain 134(2), 534-541.
  13. & Two binding sites for [3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. Journal of Cerebral Blood Flow & Metabolism 30(9), 1608-1618.
  14. & A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Annals of Neurology 68(4), 477-493.
  15. & HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. Nature Neuroscience 13(2), 180-189.
  16. & Activated Microglia Mediate Axoglial Disruption That Contributes to Axonal Injury in Multiple Sclerosis. Journal of Neuropathology and Experimental Neurology 69(10), 1017-1033.
  17. & NPY mediates basal and seizure-induced proliferation in the subcallosal zone. NeuroReport 18(10), 1005-1008.
  18. & Neuropeptide Y is important for basal and seizure-induced precursor cell proliferation in the hippocampus. Neurobiol Disease 26, 174
  19. & Sedation and Anesthesia Mediated by Distinct GABAA Receptor Isoforms. J Neurosci 23, 8607-8617.
  20. & Enhanced Learning and Memory and Altered GABAergic Synaptic Transmission in Mice Lacking the α5 Subunit of the GABAAReceptor. J Neurosci 22, 5572
  21. & Loss of the Major GABAA Receptor Subtype in the Brain Is Not Lethal in Mice. J Neurosci 21, 3409-3418.
  22. & Density and pharmacology of α5 subunit-containing GABAA receptors are preserved in hippocampus of Alzheimer’s disease patients. Neuroscience 98, 669-675.
  23. & Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor alpha1 subtype. Nature Neuroscience 3, 587-592.
  24. & Changes in [3H]zolpidem and [3H]Ro 15-1788 binding in rat globus pallidus and substantia nigra pars reticulata following a nigrostriatal tract lesion.. Brain Res 862, 280
  25. & Autoradiographic localization of α5 subunit-containing GABAA receptors in rat brain. Brain Res 822, 265